CD274 and neoplasm: Recent meta-analysis of anti-PD-1/PD-L1 therapy data pooled from 50+ studies spanning 10+ tumor types and 8,000+ patients used ROC and AUC to examine the predictive value of single-marker IHC (PD-L1), tumor mutational burden (TMB), gene expression profiling (GEP) and PD-L1 mIHC/mIF.